Sativa Wellness (AQSE and CSE: SWEL) notes today’s announcement by the Aquis Stock Exchange PLC, that the two new segments of the market have come into force. Please see Aquis Stock Exchange link for the full announcement.

Sativa Wellness has been notified by AQSE that it qualifies for the “Apex” segment of the AQSE Growth Market. In order to be eligible for admission to Apex, Sativa has succeeded in meeting, amongst other things, the following specific criteria…

“Sativa Wellness welcomes the clarity that these regulatory updates bring to the CBD wellness and medicinal cannabis industry in Europe, the US and globally. We believe that a well-regulated cannabis sector will lead to consumers benefitting from safe, compliant and quality products, such as our Goodbody CBD brands, and opens the pathway for patients to benefit from further research into the efficacy of medicinal cannabis…

We are pleased to announce that the board of directors have resolved to change the Company’s fiscal year end from July 31 to December 31, effective immediately.

By moving the Company’s reporting cycle to a calendar quarter basis in line with the operating subsidiaries of the Company, Sativa Wellness aims to reduce the time constraints and administrative expenses with having to reconcile multiple reporting periods among other related corporations.

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, as at the close of business on 30 September 2020, being the last business day prior to the date of this announcement, it had 302,592,941 common shares of no par value each in issue and admitted to trading on the AQSE Growth Market. Sativa Wellness holds no common shares in treasury…

The European Union’s highest court has ruled that CBD (Cannabidiol) is not a narcotic drug, and that a French ban on hemp derived CBD contradicts EU law. This ruling has opened the door for high quality compliant CBD companies to operate in markets across the EU. The Sativa Wellness Group Inc. welcomes this news as the company operates CBD extraction and production facilities in the UK and Europe…

We are pleased to announce that as part of Sativa Wellness’s commitment to safety and wellness in our communities, we are launching a private COVID testing clinic inside our Goodbody Wellness store in Bath on 19th November.

The clinic will be providing PCR testing for travel and work, antigen testing (results in 15 minutes) as well as antibody testing for those who want to find out if they have had COVID 19 and to see if they have developed antibodies…

Sativa Wellness (AQSE and CSE: SWEL), the fully integrated European seed to consumer CBD group with the pricing, products, and stability to meet the growing CBD market demand both now and in the medium term, wishes to announce that the Company has secured a cannabidiol (“CBD”) product listings with the “Health Store”. The Health Store is the longest established and most respected distributer in the health food industry, who supply over 800 stores in England and Ireland and a further 130 overseas retailer stores in more than 30 different countries.

Sativa Wellness, (AQSE: SWEL) (formerly, Stillcanna, Inc.), is pleased to announce that trading of its shares consisting of 302,592,941 Common Shares of no par value (“Common Shares”) will commence trading at 8.00 a.m. today on the AQSE Growth Market, with ISIN number CA80403E1043.

The Company will be dual-listed on both the Canadian Securities Exchange and the AQSE growth Market. The Company also expects to be quoted on the over-the-counter (the “OTC”) market in the United States and the Frankfurt Stock Exchange (the “FSE”) shortly.

The Company would like to sincerely thank shareholders for their patience and support during the trading halt. The Transaction was subject to requisite legislative and exchange regulatory approvals in both the United Kingdom and Canada.

Going forward, Sativa is now a true vertically-integrated European seed-to-consumer cannabidiol (“CBD”) wellness company. The Company manages the cultivation of raw materials, owns extraction, packaging and testing facilities, and has developed and marketed leading consumer brands. This complete supply chain custody model ensures that retail and wholesale customers receive pharmaceutical grade CBD products they can trust.

As part of the Sativa Group PLC’s ongoing commitment to continually deliver the highest level of regulatory compliance and substantiate ‘CBD you can trust’, the Company has become a member of the Association for the Cannabinoid Industry (ACI) Novel Food consortium and it’s landmark toxicology study, which will augment the submission of it’s own Novel Food application dossier.

Further to the Company’s news release dated September 10, 2020, Sativa wishes to provide an update on the status of the re-listing of Stillcanna Inc. (to be renamed Sativa Wellness Group Inc.) (“Stillcanna”) common shares on the Canadian Securities Exchange (the “CSE”) and the AQSE Growth Market (the “AQSE”). The Company is currently co-ordinating with Stillcanna a date of re-listing with the CSE, and continues to work diligently to fulfil the remaining conditions of re-listing.